Aquestive therapeutics receives positive fda written response for aqst-109 epinephrine sublingual film

Warren, n.j., oct. 11, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying complex delivery methods, today announced positive written feedback from the u.s. food and drug administration (fda) for its initial end-of-phase 2 (eop2) meeting request to discuss chemistry, manufacturing, and controls (cmc) for its aqst-109 epinephrine sublingual film for the treatment of severe allergic reaction including anaphylaxis.
AQST Ratings Summary
AQST Quant Ranking